Empiric Calcium in Massive Transfusion

Sponsor
University of California, Irvine (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05953376
Collaborator
(none)
30
2
35

Study Details

Study Description

Brief Summary

Calcium helps blood to clot and thereby stop bleeding. Trauma patients who experience large volume blood loss often require blood transfusions and bleeding is the most common cause of death. The purpose of this study is to see if giving intravenous calcium immediately to patients who require large volume blood transfusion will decrease transfusion requirements, vasopressor use and mortality in bleeding trauma patients.

Condition or Disease Intervention/Treatment Phase
  • Drug: Calcium Gluconate
Phase 3

Detailed Description

Advancements in the area of transfusion and blood product administration have occurred with the use of viscoelastic assays and whole blood. However, as we resuscitate trauma patients with blood products, hypocalcemia is an inadvertent side-effect. Citrate within stored blood binds calcium, causing patients to have hypocalcemia. In addition, outside of transfusion related hypocalcemia there is an independent trauma/inflammation related mechanism for hypocalcemia in the trauma patient. Furthermore, Calcium is a critical component of the coagulation cascade, and therefore a highly important component of hemostatic resuscitation. Hall et al found that patients receiving 13 or more units of PRBCs had a much higher prevalence of severe hypocalcemia and at least one ionized calcium <1.0mmol/L. Kronstedt el al reported an association between hypocalcemia and mortality in trauma patients receiving massive transfusion. Despite evidence that hypocalcemia occurs with transfusion, and evidence that hypocalcemia in patients with hemorrhagic shock may be associated with increased mortality, there are no randomized controlled trials evaluating the administration of calcium in trauma resuscitation. Currently, the Joint Trauma System revised guidelines for damage control resuscitation from 2019 recommend administering 1g of calcium after the first unit of blood transfusion, and an additional 1g after no more than 4 units of blood administration. However, these recommendations are based on small cohort studies or retrospective studies. The purpose of this study is to evaluate the efficacy of early empiric intravenous calcium administration on transfusion requirements, vasopressor use and mortality in hemorrhaging trauma patients with initiation of a massive transfusion.

All trauma patients in which massive transfusion is initiated within 6 hours of arrival will be enrolled. Two study arms will be created, one will receive 2g IV calcium with the initial transfusion and the other will only receive calcium supplementation based on routine ionized calcium levels and/or physician discretion. All critical trauma activations will get a baseline ionized calcium as part of their initial labs.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
Empiric Calcium Versus Lab Based Treatment in Massive Transfusion Trauma Patients: A Feasibility Randomized Controlled Trial
Anticipated Study Start Date :
Jan 1, 2024
Anticipated Primary Completion Date :
Dec 1, 2025
Anticipated Study Completion Date :
Dec 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Empiric calcium administration

Patients in this arm will receive 2g IV calcium with the initial transfusion

Drug: Calcium Gluconate
There will be 2 study arms, one will receive 2g IV calcium with the initial transfusion and the other will only receive calcium supplementation based on routine ionized calcium levels and/or physician discretion.
Other Names:
  • Calcium
  • No Intervention: No empiric calcium administration

    Patients in this arm will only receive calcium supplementation based on routine ionized calcium levels and/or physician discretion

    Outcome Measures

    Primary Outcome Measures

    1. Transfusion requirements [During first 24 hours of resuscitation]

      Number of packed red blood cells, whole blood, fresh frozen plasma, platelets and cryo units given

    Secondary Outcome Measures

    1. Mortality [30-day mortality]

      30-day mortality or until discharge (whichever is longer)

    2. Vasopressor use [During first 24 hours of resuscitation]

      Amount of vasopressor used within the first 24 hours measured in levophed equivalents

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Trauma patients receiving massive transfusion protocol
    Exclusion Criteria:
    • Pregnancy

    • Prisoners

    • Known history of hypercalcemia

    • Active hyperparathyroidism

    • Hemophilia

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University of California, Irvine

    Investigators

    • Principal Investigator: Jeffry Nahmias, MD, University of California, Irvine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Jeffrey Nahmias, Associate Professor of Surgery, University of California, Irvine
    ClinicalTrials.gov Identifier:
    NCT05953376
    Other Study ID Numbers:
    • 3115
    First Posted:
    Jul 20, 2023
    Last Update Posted:
    Jul 20, 2023
    Last Verified:
    Jul 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 20, 2023